Analyses of mRNA expression databases revealed that near-median expression of PARP1 by patients with FLT3 wild-type, M4/M5 AML receiving 7+3 chemotherapy is associated with a 2-fold lower death rate (HR = 0.56, p = 0.011). The gene discussed is PARP1; the disease is acute myeloid leukemia.